Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine-Cyclophosphamide for Refractory/Relapsed Adult ALL (LAL1610)
NCT01462253Phase 2Completed
- Sponsor
- GIMEMA
- Start
- Oct 2012
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of clofarabine in acute lymphoblastic leukemia (ALL), sponsored by GIMEMA. Primary endpoint: Number of Patients in Complete Remission After Induction Therapy at Day 28. Started Oct 2012; status: completed.
02
Drugs
clofarabine
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT01462253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01462253.